Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Atopic Dermatitis (AD)
Trial Locations (18)

100191

Peking University Third Hospital /ID# 257722, Beijing

110001

The First Hospital of China Medical University /ID# 257641, Shenyang

200040

Huashan Hospital, Fudan University /ID# 256456, Shanghai

200065

Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726, Shanghai

200443

Shanghai Skin Disease Hospital /ID# 257719, Shanghai

250022

Shandong Dermatological Hospital /ID# 257727, Jinan

310003

Hangzhou First People's Hospital /ID# 261867, Hangzhou

310009

The second affiliated hospital of Zhejiang University school of medicine /ID# 257723, Hangzhou

315010

Ningbo First Hospital /ID# 263884, Ningbo

350005

The First Affiliated Hospital Of Fujian Medical University /ID# 257725, Fuzhou

430022

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724, Wuhan

450003

People's Hospital of Henan Province /ID# 257736, Zhengzhou

510091

Dermatology Hospital of Southern Medical University /ID# 261862, Guangzhou

518033

The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737, Shenzhen

610017

Chengdu Second Municipal People's Hospital /ID# 257732, Chengdu

610041

West China Hospital, Sichuan University /ID# 257720, Chengdu

610072

Sichuan Provincial People's Hospital /ID# 263898, Chengdu

710004

Second Affiliated Hospital of Xian Jiaotong University /ID# 257733, Xi'an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY